Core Viewpoint - The collaboration between LianKang Biotechnology Group, Wenzhou Medical University National Engineering Research Center, and Wenzhou Ouhai District People's Government aims to enhance research and development in the fields of skin, ophthalmology, and metabolic-related diseases, accelerating strategic implementation processes [1][2] Group 1: Collaboration Details - A tripartite strategic cooperation agreement has been signed to establish the "LianKang-Wenzhou Medical University Translational Medicine Joint Innovation Laboratory" [1] - The collaboration will leverage each party's strengths in research, industry, and policy to conduct comprehensive cooperation from basic research to clinical transformation and industrialization [2] Group 2: Research Focus - The partnership will explore the synergistic mechanisms of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair [1] - New formulations and delivery systems will be developed targeting diseases such as non-alcoholic steatohepatitis (NASH) and asthma, addressing significant unmet clinical needs in these areas [1] Group 3: Strategic Implications - This collaboration is expected to enhance the group's research efficiency and success rates in the biopharmaceutical innovation sector, shortening product development cycles [2] - The partnership will also facilitate the expansion of existing products into more clinical applications, reinforcing the group's competitive edge in the EGF/FGF niche [2] - The board views this collaboration as a key initiative to deepen the "government-university-enterprise" synergy and integrate into national-level innovation platforms, significantly accelerating the development and transformation of cutting-edge innovation pipelines [2]
联康生物科技集团与温医大国家工程研究中心及温州市瓯海区人民政府达成战略合作